0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Validation of Plasma Branched Chain Amino Acids as Biomarkers in Huntington Disease FREE

Fanny Mochel, MD, PhD; Sandra Benaich, MS; Daniel Rabier, MD; Alexandra Durr, MD, PhD
[+] Author Affiliations

Author Affiliations: Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) S975/Centre National de la Recherche Scientifique, UMR 7225, Centre de Recherche Institut du Cerveau et de la Moelle (Drs Mochel and Durr); Assistance-Publique-Hôpitaux de Paris, Département de Génétique et Cytogénétique, Hôpital de La Salpêtrière (Drs Mochel and Durr and Ms Benaich); and Laboratoire de Biochimie Métabolique, Hôpital Necker-Enfants Malades (Dr Rabier), Paris, France.


Arch Neurol. 2011;68(2):264-271. doi:10.1001/archneurol.2010.358.
Text Size: A A A
Published online

While investigating body weight in a cohort of 32 patients at an early stage of Huntington disease (HD) and presymptomatic HD gene carriers, we found a significant decrease in the plasma branched-chain amino acids (BCAA) valine, leucine, and isoleucine in the HD group compared with 21 healthy controls. This systemic metabolic defect, which is indicative of hypercatabolism, was associated with early body weight loss in the HD group.1 We wanted to (1) try to replicate our initial findings in a larger HD cohort, and (2) assess the feasibility of using plasma BCAA as a biomarker in HD, ie, in a less controlled research environment than the initial study.1

After approval by the institutional ethics committees (Institut National de la Santé et de la Recherche Médicale, Recherche Biomédicale 03-48), we measured fasting levels of plasma BCAA as previously described1 in 16 presymptomatic HD gene carriers and 70 patients with HD at a mild, moderate, or severe stage of the disease who were seen consecutively at our outpatient clinic. Our control group consisted of 21 healthy individuals, previously described.1 To evaluate the multivariate associations, the LASSO (Least Absolute Shrinkage and Selection Operator) model selection technique was used with the adjusted r2 statistic as the model selection criterion. The number of CAG codons was forced into these models with the Unified Huntington Disease Rating Scale (UHDRS), age, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), sex, and their 2-way interactions as possible covariates.

Plasma valine, leucine, and isoleucine levels were significantly lower in the HD group compared with controls (P = .02, <.001, and .002, respectively). In addition, we found a significant decrease of valine, leucine, and isoleucine in moderately affected patients and patients at a severe stage of the disease (Figure). Leucine was also significantly decreased in patients at a very mild stage of the disease and in presymptomatic individuals (Figure). Simple linear regression showed that plasma BCAA were not correlated with the UHDRS. However, we found that valine was negatively correlated with the number of CAG repeats (P = .01, adjusted r2 = 0.086). After adjusting for BMI and sex, we confirmed that there was a negative association between valine and CAG repeats (P = .02, adjusted r2 = 0.309). For every 1-unit increase in CAG, valine decreased by −3.33. We also found a significant association between leucine and CAG repeats (P = .04, adjusted r2 = 0.372), with an association dependent on BMI due to the interaction. For every 1-unit increase in CAG, leucine decreased by −1.50 for the mean value of BMI (23.2).

Place holder to copy figure label and caption
Figure.

Plasma levels of valine, leucine, and isoleucine in presymptomatic individuals (mean [SD] Unified Huntington Disease Rating Scale [UHDRS] score, 0.3 [0.9]) and patients at a mild (mean [SD] UHDRS score, 14.1 [6.5]), moderate (mean [SD] UHDRS score, 38.9 [6.9]), or severe (mean [SD] UHDRS score, 68.9 [15.3]) stage of disease compared with controls. Circles and triangles denote outliers that are farther than 1.5 and 3 interquartile ranges respectively from the nearer edge of the box. *P < .05; †P < .001.

Graphic Jump Location

We confirmed, in a larger cohort of patients with HD at different stages of the disease as well as presymptomatic HD gene carriers sampled consecutively, that plasma BCAA are relevant and accessible biomarkers in HD. After adjusting for BMI and sex, we showed an inverse correlation between the plasma levels of valine and leucine and number of CAG repeats, the primary determinant of HD severity. Of the 3 BCAA, leucine was of particular interest because it was significantly reduced in patients at an early stage of the disease and, more remarkably, in presymptomatic individuals. Leucine is a well-known activator of mTor (mammalian target of rapamycin),2 which regulates protein synthesis and whose inhibition results in increased autophagic proteolysis.3 Akt, which has been shown to be altered in HD rat brain and in peripheral blood cells of patients with HD,4 also mediates the activity of mTor. Therefore, reduced leucine levels and altered Akt activation in HD may both result in mTor inhibition and exacerbation of proteolysis in HD.5 The significant correlation of BCAA with CAG repeats but not with UHDRS stages suggests that this biomarker is closely related to the primary defect in HD rather than to neuronal degeneration.

ARTICLE INFORMATION

Correspondence: Dr Mochel, INSERM UMR S975, Department of Genetics, Hôpital de La Salpêtrière, 47 Boulevard de l'Hôpital, Bâtiment Nouvelle Pharmacie, 4ème étage, 75013 Paris, France (fanny.mochel@upmc.fr).

Financial Disclosure: None reported.

Additional Contributions: We wish to thank warmly the patients and presymptomatic individuals for their participation in this study. We are also thankful to Derek Blankenship, PhD, for statistical support.

Mochel  FCharles  PSeguin  F  et al.  Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007;2 (7) e647
PubMed Link to Article
Flier  JS Neuroscience: regulating energy balance: the substrate strikes back. Science 2006;312 (5775) 861- 864
PubMed Link to Article
Hay  NSonenberg  N Upstream and downstream of mTOR. Genes Dev 2004;18 (16) 1926- 1945
PubMed Link to Article
Colin  ERégulier  EPerrin  V  et al.  Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005;21 (6) 1478- 1488
PubMed Link to Article
Heng  MYDuong  DKAlbin  RL  et al.  Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 2010;19 (19) 3702- 3720
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Plasma levels of valine, leucine, and isoleucine in presymptomatic individuals (mean [SD] Unified Huntington Disease Rating Scale [UHDRS] score, 0.3 [0.9]) and patients at a mild (mean [SD] UHDRS score, 14.1 [6.5]), moderate (mean [SD] UHDRS score, 38.9 [6.9]), or severe (mean [SD] UHDRS score, 68.9 [15.3]) stage of disease compared with controls. Circles and triangles denote outliers that are farther than 1.5 and 3 interquartile ranges respectively from the nearer edge of the box. *P < .05; †P < .001.

Graphic Jump Location

Tables

References

Mochel  FCharles  PSeguin  F  et al.  Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007;2 (7) e647
PubMed Link to Article
Flier  JS Neuroscience: regulating energy balance: the substrate strikes back. Science 2006;312 (5775) 861- 864
PubMed Link to Article
Hay  NSonenberg  N Upstream and downstream of mTOR. Genes Dev 2004;18 (16) 1926- 1945
PubMed Link to Article
Colin  ERégulier  EPerrin  V  et al.  Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005;21 (6) 1478- 1488
PubMed Link to Article
Heng  MYDuong  DKAlbin  RL  et al.  Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 2010;19 (19) 3702- 3720
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

882 Views
1 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs